AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$XBIO

Xenetic Biosciences, Inc.

Price · $XBIOvia TradingView
AI sentiment · 7d2 articles
AUG 2net (bullish − bearish)AUG 8
Bullish
0
Neutral
2
Bearish
0
Insider · 30dFeed →

No SEC Form 4 filings for $XBIO in the last 30 days.

Top stories · $XBIOMore →
AUG 7·finanznachrichten.deMed

Xenetic Biosciences, Inc.: Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Pla

Xenetic Biosciences (NASDAQ:XBIO) reported Q2 2026 results for the quarter ended June 30. Royalty revenue rose about 12% to about $0.7M, while R&D fell about 16% to about $0.6M. G&A increased about 64% to about $1.1M, driving a net loss of about $0.9M. Cash was about $6.5M. The company cited ASCO preclinical/translational data and a PeriNess study approval.

AUG 7·SEC EDGAR 8-K

Xenetic Biosciences, Inc. (XBIO): Results of Operations and Financial Condition

Xenetic Biosciences, Inc. (XBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Xenetic Biosciences, Inc. 8-K false 0001534525 0001534525 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FORM 8-K ________________________ CURRENT REPORT Purs

JAN 20·Times Herald-Record

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. has extended its collaboration with The Scripps Research Institute and Dr. Alexey Stepanov for an additional four months to further develop its DNase platform. This collaboration focuses on advancing Xenetic's systemic DNase I candidate, XBIO-015, in combination with CAR T-cell therapies for various cancers, building on preclinical studies that showed significant improvements in reducing tumor burden and extending survival. The company is progressing its DNase-based technology towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.

XBIO sentiment & insider activity

Over the past 7 days, alphai's AI scored 2 news stories mentioning XBIO (Xenetic Biosciences, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.

Recent XBIO coverage spans financial news and earnings.

What's driving XBIO

  • The print is modestly positive on recurring royalty momentum and preclinical translational progress, but the cash burn and higher G&A tied to a strategic review keep risk elevated.

    finanznachrichten.de · Aug 7, 2026

  • This is a quarterly results disclosure via 8-K, but the scraped text does not include the actual financial figures or guidance.

    SEC EDGAR 8-K · Aug 7, 2026

  • Xenetic Biosciences' extension of collaboration with Scripps Research indicates ongoing progress in DNase platform technology, potentially supporting positive sentiment for the company's stock.

    Times Herald-Record · Jan 20, 2026

  • Xenetic Biosciences (XBIO) maintains a neutral stance with minimal recent ranking shifts.

    Benzinga · Oct 10, 2025

  • Xenetic Biosciences (XBIO) reported a significant earnings surprise (+29.69%) but missed revenue estimates (-7.81%) for Q2 2025. The stock's neutral sentiment suggests limited immediate directional bias, but the earnings surprise could influence short-term trading.

    Zacks Commentary · Aug 12, 2025

alphai scores every news story that mentions XBIO with an AI model for sentiment and relevance, and aggregates insider trades from Xenetic Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $XBIO

Score
AUG 7$XBIOMedfinanznachrichten.de

Xenetic Biosciences, Inc.: Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Pla

Xenetic Biosciences (NASDAQ:XBIO) reported Q2 2026 results for the quarter ended June 30. Royalty revenue rose about 12% to about $0.7M, while R&D fell about 16% to about $0.6M. G&A increased about 64% to about $1.1M, driving a net loss of about $0.9M. Cash was about $6.5M. The company cited ASCO preclinical/translational data and a PeriNess study approval.

4 min read
AUG 7$XBIOLowSEC EDGAR 8-K

Xenetic Biosciences, Inc. (XBIO): Results of Operations and Financial Condition

Xenetic Biosciences, Inc. (XBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Xenetic Biosciences, Inc. 8-K false 0001534525 0001534525 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FORM 8-K ________________________ CURRENT REPORT Purs

2 min read
JAN 20$XBIOHighTimes Herald-Record

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. has extended its collaboration with The Scripps Research Institute and Dr. Alexey Stepanov for an additional four months to further develop its DNase platform. This collaboration focuses on advancing Xenetic's systemic DNase I candidate, XBIO-015, in combination with CAR T-cell therapies for various cancers, building on preclinical studies that showed significant improvements in reducing tumor burden and extending survival. The company is progressing its DNase-based technology towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.

3 min read

Related tickers

More in Biotechnology